Human CLL cells show aberrant BCR signaling, whereby the downstream Btk/Plcγ2/Ca2+ and PI3K/Akt pathways are thought to be constitutively activated, resulting in increased proliferation and survival [8–10]. The gene discussed is PLCG2; the disease is B-cell chronic lymphocytic leukemia.